ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: Is it really applicable?  by Wu, Jian et al.
Letters to the EditorART score for retreatment with transarterial chemoembolization in
patients with hepatocellular carcinoma: Is it really applicable?To the Editor:
We read with great interest the work by Hucke et al. published in
the Journal of Hepatology [1]. The authors have already developed
the ART score, the Assessment for Retreatment with Transarterial
Chemoembolization (TACE), to guide the decision on whether
re-treating hepatocellular carcinoma (HCC) patients with a fur-
ther TACE in their last paper published in Hepatology [2]. In their
study, ART score differentiated patients into two groups (0–1.5
points; P2.5 points) with distinct prognosis (median OS:23.7 vs.
6.6 months; p <0.001). Then, they concluded that an ART score
P2.5 points prior to second TACE identiﬁed patients who may
not beneﬁt from further TACE sessions. In this article, they just
intended to validate the prognostic performance of the ART score
before TACE-3 and 4 and the sequential assessment of ART score
prior to each TACE session. Patients with intermediate HCC who
received at least three TACE sessions (each interval between
two adjacent sessions 690 days) were the subjects of their study.
In spite of the thrilling results of this article, we do have some
questions concerning their study.
To begin with, there are studies denoting that approximately
50% of HCC patients do not respond to the ﬁrst TACE [3,4]. We
acknowledge that maybe there exist patients who have no
response to TACE-1 and possess an increase of Child-Pugh score
of 1 point, then their ART score should be 2.5 points, which
would preclude them from further TACE sessions according toFig. 1. Dynamic changes of lipiodol in the tumor lesion. (A) Baseline contrast-enhan
11 cm. At that time, liver function was classiﬁed as Child-Pugh A5. (B) The contrast-e
uptake of lipiodol in the tumor lesion. (C) Sixteen-week CT scan after the ﬁrst TACE s
2.5 according to ART score (albumin 32.1 g/L, Child-Pugh A6). We still performed the
shows complete lipiodol deposition. Tumor response was complete response accordi
lipiodol deposition.
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Open access under CC BY-NC-ND license.the ART score system (Figs. 1 and 2). However, almost half of
these non-responders would show a signiﬁcant response and
improved survival after a second TACE [4], intimating they could
not beneﬁt from further TACE sessions if assessed by the ART
score system. Additionally, some experts recommend we per-
form at least two TACE sessions on HCC patients before chang-
ing treatment strategy [4,5]. Hence, we contend that the ART
score should be determined at the time following TACE-2 so
as to beneﬁt those initial non-responders who respond to the
second TACE.
Moreover, the authors claimed that the ART score remained a
signiﬁcant prognostic factor regardless of the TACE techniques,
which seemed to be veriﬁed by the data in Supplementary
Fig. 1A–C. We, however, notice that the data in Supplementary
Table 2 seem to contradict with their conclusion. The ﬁrst p value
in Supplementary Table 2 is 0.002, which is statistically signiﬁ-
cant, denoting that TACE techniques are likely to exert some
effects on the ART-score changes. More importantly, researches
indicate that TACE with DC bead showed a better treatment
response compared with conventional TACE [6–8] and TAE had
shown no signiﬁcant survival beneﬁt [9,10]. We can make the
conclusion that different treatment responses of the three TACE
techniques could result in the changes of ART-score. Accordingly,
we could not reach a consensus with the authors that TACE
techniques do not have effects on the ART scores.ced CT scan shows a tumor lesion in the right lobe of liver with maximum diameter
nhanced CT obtained 2 weeks after ﬁrst TACE performance reveals large amount of
hows viable tumor and lipiodol disappearance. At that time patient was graded as
third TACE treatment for this patient. (D) Eight-week CT scan after the third TACE
ng to EASL criteria. (E) Sixteen-week CT scan after the third TACE shows complete
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Fig. 2. Angiography of tumor before and after TACE. (A) DSA angiography
shows tumor staining in the right lobe of the liver in the ﬁrst TACE performance.
(B) The tumor staining disappears after chemoembolization. (C) DSA examination
shows tumor staining in the third TACE session. (D) The tumor staining
disappears after the third TACE procedure.
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JOURNAL OF HEPATOLOGYIn addition, the authors deﬁned objective tumor response as
complete response (CR) and partial response (PR) in this article,
quite different from the deﬁnition in their previous article, which
excluded the complete response (CR)with the reason that patients
with complete response (CR) following the ﬁrst TACE did not
receive a further TACE session. We wonder whether the patients
with complete response (CR) after TACE-2 or TACE-3 received
further TACE sessions in their institutions. We suppose that the
distinct deﬁnitions of objective tumor response may diminish
the credibility of their study. All the above demonstrates that
the ART score is not as validated as we previously supposed.
All in all, further study is needed to fully validate the clinical
practice of ART-score regardless of its remarkable signiﬁcance in
helping distinguish patients who will beneﬁt from repeated
TACE.
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manuscript.Reply to the Letters to the Editor regarding the sequential ART-Score
To the Editor:
We would like to thank Yousuf and colleagues for the thoughtful
comments on our work regarding the sequential use of the ART
score to select patients for retreatment with TACE [1]. They are
right in commenting that the Child-Pugh score (CPS) consists of
5 variables but the reason why we use the change in CPS was that
in our uni- and multivariate analysis from the original ART-score
manuscript, the change in composite CPS was a better predictor
for survival than the change in the individual variables included
in the CPS [2]. In addition, from a practical point of view, the
CPS has to be calculated to evaluate the patient’s suitability with
regards to liver function for the selection for any treatment
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